Organic diseases of the digestive system (gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver, etc.) .
Diagnosis of other functional diseases of the digestive system, such as dyskinesia of cystic duct or gallbladder, irritable bowel syndrome, etc.
Discontinuation of proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations less than 7 days prior to randomization.
H. Pylori eradication within 2 months before study entry.
Intestinal infection within 2 months before study entry.
Known history of/suspected malignant neoplasm of various sites.
Prior diagnosis of a class IV cardiovascular disease (according to the New York Heart Association, 1964), hypothyroidism, diabetes mellitus, chronic kidney disease (С3-5), or disease of liver with portal hypertension and/or severe decompensation (Child-Pugh score > 6).
Other severe coexisting morbidity which, in the investigator's opinion, can prevent the patient from participating in the study.
Allergy/intolerance to any of the components of medications used in the treatment.
Pregnancy, breast-feeding.
Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the investigational drugs.
Planned hospitalization during the study period, for any diagnostic or treatment procedures.
Drug addiction, alcohol use in the amount over 2 units of alcohol a day, mental diseases.
Intake of medicines listed in the section 'Prohibited concomitant treatment' for 1 month prior to the enrollment in the trial.
Participation in other clinical trials within 3 months to the enrollment in this study.
Patient is related to the research staff of the clinical investigative site who are directly involved in the trial or is the immediate family member of the investigator. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
Patient works for OOO "NPF "MATERIA MEDICA HOLDING" (i.e., is the company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family).

NCT03119766_exc_T1
Condition
Organic diseases
NCT03119766_exc_T2
Qualifier
digestive system
NCT03119766_exc_T3
Condition
gastro-oesophageal reflux disease (GERD)
NCT03119766_exc_T4
Condition
ulcer
NCT03119766_exc_T5
Condition
chronic pancreatitis
NCT03119766_exc_T6
Condition
cholelithiasis
NCT03119766_exc_T7
Condition
fatty liver disease
NCT03119766_exc_T8
Condition
hepatitis
NCT03119766_exc_T9
Condition
cirrhosis of liver
NCT03119766_exc_T10
Scope
gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver
NCT03119766_exc_T11
Scope
Organic diseases of the digestive system
NCT03119766_exc_T12
Condition
functional diseases
NCT03119766_exc_T13
Qualifier
digestive system
NCT03119766_exc_T14
Scope
functional diseases of the digestive system
NCT03119766_exc_T15
Condition
dyskinesia of cystic duct
NCT03119766_exc_T16
Condition
yskinesia of allbladder,
NCT03119766_exc_T17
Condition
irritable bowel syndrome
NCT03119766_exc_T18
Scope
dyskinesia of cystic duct or gallbladder, irritable bowel syndrome
NCT03119766_exc_T19
Drug
proton pump inhibitors
NCT03119766_exc_T20
Drug
propulsives
NCT03119766_exc_T21
Drug
antispasmodics
NCT03119766_exc_T22
Drug
antacids
NCT03119766_exc_T23
Drug
bismuth preparations
NCT03119766_exc_T24
Observation
Discontinuation
NCT03119766_exc_T25
Temporal
less than 7 days prior to randomization
NCT03119766_exc_T26
Scope
proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations
NCT03119766_exc_T27
Procedure
H. Pylori eradication
NCT03119766_exc_T28
Temporal
within 2 months before study entry
NCT03119766_exc_T29
Reference_point
study entry
NCT03119766_exc_T30
Reference_point
randomization
NCT03119766_exc_T31
Condition
Intestinal infection
NCT03119766_exc_T32
Temporal
within 2 months before study entry
NCT03119766_exc_T33
Reference_point
study entry
NCT03119766_exc_T34
Observation
history of
NCT03119766_exc_T35
Mood
suspected
NCT03119766_exc_T36
Condition
malignant neoplasm
NCT03119766_exc_T37
Qualifier
various sites
NCT03119766_exc_T38
Scope
history of/suspected
NCT03119766_exc_T39
Condition
cardiovascular disease
NCT03119766_exc_T40
Measurement
New York Heart Association
NCT03119766_exc_T41
Value
class IV
NCT03119766_exc_T42
Condition
hypothyroidism
NCT03119766_exc_T43
Condition
diabetes mellitus
NCT03119766_exc_T44
Condition
chronic kidney disease
NCT03119766_exc_T45
Measurement
С
NCT03119766_exc_T46
Value
3-5
NCT03119766_exc_T47
Condition
disease of liver
NCT03119766_exc_T48
Condition
portal hypertension
NCT03119766_exc_T49
Condition
severe decompensation
NCT03119766_exc_T50
Scope
disease of liver with portal hypertension
NCT03119766_exc_T51
Measurement
Child-Pugh score
NCT03119766_exc_T52
Value
> 6
NCT03119766_exc_T53
Scope
Child-Pugh score > 6
NCT03119766_exc_T54
Temporal
coexisting
NCT03119766_exc_T55
Condition
morbidity
NCT03119766_exc_T57
Condition
Allergy
NCT03119766_exc_T58
Condition
intolerance
NCT03119766_exc_T59
Drug
components of medications used in the treatment
NCT03119766_exc_T60
Scope
Allergy/intolerance
NCT03119766_exc_T61
Condition
Pregnancy
NCT03119766_exc_T62
Observation
breast-feeding
NCT03119766_exc_T64
Mood
Planned
NCT03119766_exc_T65
Procedure
hospitalization
NCT03119766_exc_T66
Temporal
during the study period
NCT03119766_exc_T67
Procedure
treatment procedures
NCT03119766_exc_T68
Procedure
or treatme 
Drug add
NCT03119766_exc_T69
Scope
diagnostic or treatment procedures
NCT03119766_exc_T70
Condition
Drug addiction
NCT03119766_exc_T71
Measurement
alcohol use
NCT03119766_exc_T72
Value
over 2 units of alcohol a day
NCT03119766_exc_T73
Condition
mental diseases
NCT03119766_exc_T74
Drug
medicines
NCT03119766_exc_T75
Qualifier
listed in the section 'Prohibited concomitant treatment'
NCT03119766_exc_T76
Temporal
1 month prior to the enrollment in the trial
NCT03119766_exc_T77
Reference_point
the enrollment in the trial
NCT03119766_exc_T80
Person
works for OOO "NPF "MATERIA MEDICA HOLDING"
NCT03119766_exc_T81
Person
company's employee
NCT03119766_exc_T82
Person
temporary contract worker
NCT03119766_exc_T83
Person
appointed official
NCT03119766_exc_T84
Observation
responsible for carrying out the research or their immediate family
NCT03119766_exc_T85
Scope
company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family